A251280 Stock Overview

A biotechnology company, develops medicine with angiogenesis inhibitors for treating angiogenesis-related diseases. More details

A251280 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Has not reported any financial data

Shareholders have been diluted in the past year

Does not have a meaningful market cap (₩20B)

My Notes

Capture your thoughts, links and company narrative

Angiolab, Inc. Competitors

Clinomics

KOSDAQ:A352770

₩21.4b

OLIPASS

KOSDAQ:A244460

₩26.5b

GeneBioTech Ltd

KOSDAQ:A086060

₩29.4b

Cell Bio Human TechLtd

KOSDAQ:A318160

₩29.2b

Price History & Performance

Summary of share price highs, lows and changes for Angiolab
Historical stock prices
Current Share Price	₩7,590.00
52 Week High	₩9,200.00
52 Week Low	₩3,000.00
Beta	0
1 Month Change	-9.64%
3 Month Change	-3.92%
1 Year Change	-2.69%
3 Year Change	-16.87%
5 Year Change	-55.48%
Change since IPO	62.01%

Recent updates

Shareholder Returns

	A251280	KR Biotechs	KR Market
7D	2.6%	0.1%	-1.6%
1Y	-2.7%	16.9%	-9.1%

Return vs Industry: A251280 underperformed the KR Biotechs industry which returned 16.9% over the past year.

Return vs Market: A251280 exceeded the KR Market which returned -9.1% over the past year.

Price Volatility

Is A251280's price volatile compared to industry and market?
A251280 volatility
A251280 Average Weekly Movement	8.3%
Biotechs Industry Average Movement	8.7%
Market Average Movement	6.6%
10% most volatile stocks in KR Market	12.6%
10% least volatile stocks in KR Market	3.3%

Stable Share Price: A251280 has not had significant price volatility in the past 3 months compared to the KR market.

Volatility Over Time: A251280's weekly volatility (8%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1999	n/a	Min-Young Kim	www.angiolab.co.kr

Angiolab, Inc., a biotechnology company, develops medicine with angiogenesis inhibitors for treating angiogenesis-related diseases. Its Phase I products consist of AL101-PSO for psoriasis. The company’s Phase II a clinical trial products include AL101- NASH for the treatment of non-alcoholic steatohepatitis; AL101-OME, for otitis media with effusion; and AL102-PDT for periodontitis.

Angiolab, Inc. Fundamentals Summary

How do Angiolab's earnings and revenue compare to its market cap?
A251280 fundamental statistics
Market cap	₩19.91b
Earnings (TTM)	₩0
Revenue (TTM)	n/a

n/a

P/E Ratio

n/a

P/S Ratio

Is A251280 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A251280 income statement (TTM)
Revenue	₩0
Cost of Revenue	₩0
Gross Profit	₩0
Other Expenses	₩0
Earnings	₩0

Last Reported Earnings

n/a

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did A251280 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/20 15:59
End of Day Share Price	2024/12/20 00:00
Earnings	N/A
Annual Earnings	N/A

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Angiolab, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Seong Man Yoo	Hyundai Motor Securities Co. Ltd.